Chemotherapy with Epirubicin and Paclitaxel for Breast Cancer during Pregnancy: Case Report and Review of the Literature

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5225-5229

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Fanucchi, Antonio ^a   Nardini, Vincenzo ^a   Roncella, Manuela ^b   Conte, Pier Franco ^b   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Santa Chiara Hospital   (Italy)

Author keywords

Breast cancer; Chemotherapy; Epirubicin; P glycoprotein; Paclitaxel; Pregnancy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GLYCOPROTEIN P; GONADORELIN DERIVATIVE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CESAREAN SECTION; CONGENITAL MALFORMATION; DRUG SAFETY; FEMALE; FETUS ECHOGRAPHY; FETUS MALFORMATION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; NEUTROPENIA; PREGNANCY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 0842278691     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Hoover HC Jr: Breast cancer during pregnancy and lactation. Surg Clin North Am 70: 1151-1163, 1990.
2. Mignot L: Cancer of the breast and pregnancy: the point of view of the breast cancer specialist. Bull Cancer 89: 772-778, 2002.
3. Fiorica JV: Special problems. Breast cancer and pregnancy. Obstet Gynecol Clin North Am 21: 721-732, 1994.
4. Helewa M, Levesque P, Provencher D, Lea RH, Rosolowich V and Shapiro HM: Breast cancer, pregnancy, and breastfeeding. J Obstet Gynaecol Can 24: 164-180, 2002.
5. Gwyn KM and Theriault RL: Breast cancer during pregnancy. Curr Treat Options Oncol 1: 239-243, 2000.
6. Mathieu E, Merviel P, Antoine JM and Uzan S: Cancer and pregnancy: the point of view of the obstetrician. Bull Cancer 89: 758-764, 2002.
7. Inbar MJ and Ron IG: Breast-conservative surgery and adjuvant chemotherapy in pregnancy. Acta Obstet Gynecol Scand 75: 765-767,1996.
8. Yip CH, Taib NA, Abdullah MM and Wahid I: Breast cancer in pregnancy- our experience with six patients in the University Hospital, Kuala Lumpur. Med J Malaysia 55: 308-310, 2000.
9. Metz JM, Schultz DJ, Fox K, Mathews A, Glick J and Solin LJ: Analysis of outcomes for high-risk breast cancer based on interval from surgery to postmastectomy radiation therapy. Cancer J 6: 324-330, 2000.
10. Pautier P, Lhomme C and Morice P: Cancer and pregnancy: the point of view of the chemotherapy oncologist. Bull Cancer 89: 779-785, 2002.
11. Leslie KK: Chemotherapy and pregnancy. Clin Obstet Gynecol 45: 153-164, 2002.
12. Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU and Hortobagyi GN: Management of breast cancer during pregnancy using a standardized protocol J Clin Oncol 17: 855-861, 1999.
13. Sood AK, Shahin MS and Sorosky JI: Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol 83: 599-600, 2001.
14. De Santis M, Lucchese A, De Carolis S, Ferrazani S and Caruso A: Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care 9: 235-237, 2000.
15. Clive S and Dixon JM: The value of adjuvant treatment in young women with breast cancer. Drugs 62: 1-11, 2002.
16. Pacifici GM and Nottoli R: Placental transfer of drugs administered to the mother. Clin Pharmacokinetic 28: 235-269, 1995.
17. Doll DC, Ringerberg QS and Yarbro JW: Management of cancer during pregnancy. Arch Intern Med 148: 2058-2064, 1988.
18. Doll DC, Ringenberg QS and Yarbro JW: Antineoplastic agents and pregnancy. Semin Oncol 16: 337-346,1989.
19. Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA and Golabi M: Apparent cyclophosphamide [cytoxan] embryopathy: a distinct phenotype? Am J Med Genet 86: 237-241,1999.
20. Powell HR and Ekert H: Methotrexate-induced congenital malformations. Med J Aust 2: 1076-1077, 1971.
21. Warkany J: Aminopterin and methotrexate: folic acid deficiency. Teratology 17: 353-358, 1978.
22. Stephens JD, Golbus MS, Miller TR, Wilber RR and Epstein CJ: Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. Am J Obstet Gynecol 137: 747-749, 1980.
23. Grohard P, Akbaraly JP, Saux MC, Gimenez S, Robert J, Brachet-Liermain A and Leng JJ: Transplacental passage of doxorubicin. J Gynecol Obstet Biol Reprod 18: 595-600, 1989.
24. Roboz J, Gleicher N, Wu K, Chahinian P, Kerenyi T and Holland J: Does doxorubicin cross the placenta? Lancet 2: 1382-1383, 1979.
25. Gaillard B, Leng JJ, Grellet J, Ducint D and Saux MC: Transplacental passage of epirubicin. J Gynecol Obstet Biol Reprod 24: 63-68, 1995.
26. MacFarland A, Abramovich DR, Ewen SW and Pearson CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem 26: 417-423, 1994.
27. Nakamura Y, Ikeda S, Furukawa T, Sumizawa T, Tani A, Akiyama S and Nagata Y: Function of P-glycoprotein expressed in placenta and mole. Biochem Biophys Res Commun 235: 849-853, 1997.
28. Utoguchi N, Chandorkar GA, Avery M and Audus KL: Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. Reprod Toxicol 14: 217-224, 2000.
29. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ and Marin JJ: Expression of members of the multi-drug resistance protein family in human term placenta. Am J Physiol Regul Integr Comp Physiol 279: 1495-1503, 2000.
30. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J and Buclin T: Transplacental passage of protease inhibitors at delivery. AIDS 16: 889-893, 2002.
31. Lin JH and Yamazaki M: Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42: 59-98, 2003.
32. Moscow JA and Cowan KH: Multidrug resistance. J Natl Cancer Inst 80: 14-20, 1988.
33. Johnson WW: P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find Exp Clin Pharmacol 24: 501-514, 2002.
34. Geney R, Ungureanu M, Li D and Ojima I: Overcoming multidrug resistance in taxane chemotherapy. Clin Chem Lab Med 40: 918-925, 2002.
35. Galmarini CM: P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs. J Exp Ther Oncol 2: 146-152, 2002.
36. Merei J, Hasthorpe S, Farmer P and Hutson JM: Visceral anomalies in prenatally adriamycin-exposed rat fetuses: a model for the VATER association. Pediatr Surg Int 15: 11-16, 1999.
37. Liu MI and Hutson JM: Ontogeny of bladder agenesis in rats induced by adriamycin. BJU Int 87: 556-561, 2001.
38. Merei JM: Embryogenesis of adriamycin-induced hindgut atresia in rats. Pediatr Surg 18: 36-39, 2002.
39. Turchi JJ and Villasis C. Anthracyclines in the treatment of malignancy in pregnancy. Cancer 61: 435-440, 1988.
40. Aviles A, Diaz-Maqueo JC, Talavera A, Guzman R and Garcia EL: Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 36: 243-248, 1991.
41. Barni S, Ardizzoia A, Zanetta G, Strocchi E, Lissoni P and Tancini G: Weekly doxorubicn chemotherapy for breast cancer in pregnancy. A case report. Tumori 78: 349-350, 1992.
42. Veneri D, Todeschini G, Pizzolo G, Franchini M, Ambrosetti A, Vassanelli A, Bressan F and Diani F: Acute leukemia and pregnancy. Case report. Clin Exp Obstet Gynecol 23: 112-115, 1996.
43. Merimsky O, Le Chevalier T, Missenard G, Lepechoux C, Cojean-Zelek I, Mesurolle B and Le Cesne A: Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in third trimester. Ann Oncol 10: 345-350, 1999.
44. Goldwasser F, Pico JL, Cerrina J, Fernandez H, Pons JC, Cosset JM and Hayat M: Successful chemotherapy including epirubicin in a pregnant non-Hogdkin's lymphoma patient. Leuk Lymphoma 20: 173-176, 1995.
45. Meyer-Wittkopf M, Barth H, Emons G and Schmidt S: Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol 18: 62-66, 2001.
46. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR and Schinkel AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104: 1441-1447, 1999.